Despite the widespread popularity of GLP-1 medications in the U.S., nearly three in four diabetes patients stop treatment within a year. While most research focuses on claims data and discontinuation rates, the patient experience behind long-term adherence remains under-explored. To better understand this, Thrivable collected 3,500 open-ended audio responses from 591 people with type 1 and type 2 diabetes using GLP-1s. The findings revealed that patients often succeed despite the healthcare system, not because of it.

UPCOMING WEBINAR

The Great GLP-1 Shift: How Patient Mindset Is Reshaping Diabetes Care, Support, and Strategy

Join us on Wednesday, June 24 at 12 p.m. ET for a multi-perspective discussion featuring a patient, a healthcare provider, and a researcher on new findings from Thrivable’s latest 365 report, exploring patient control, confidence, and the mental health side of GLP-1 use in diabetes.

Guests: 

• Maria Muccioli | Research Director at Thrivable | "The Researcher"

• Gary Scheiner, MS, CDCES, FADCES | Founder and Clinical Director at Integrated Diabetes Services | “The HCP”

• Liz | Person living with diabetes | Mounjaro user | "The Patient"

Host: 

• Sara Epstein | Product Director at Thrivable